How to buy Protagonist Therapeutics stock (PTGX)

Protagonist Therapeutics is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $41.49 – an increase of 1% over the previous week. Protagonist Therapeutics employs 126 staff and has a trailing 12-month revenue of around $323.8 million.

Our top picks for where to buy Protagonist Therapeutics stock

Buy Protagonist Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Protagonist Therapeutics stock price (NASDAQ: PTGX)

Use our graph to track the performance of PTGX stocks over time.

Protagonist Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$41.49
52-week range	$21.43 - $48.89
50-day moving average more info button	$44.26
200-day moving average more info button	$36.96
Wall St. target price	$57.50
PE ratio more info button	14.2409
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.74

Is it a good time to buy Protagonist Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protagonist Therapeutics price performance over time

Historical closes compared with the close of $41.49 from 2024-12-20

1 week (2024-12-13)	1.00%
1 month (2024-11-22)	-10.70%
3 months (2024-09-20)	-12.34%
6 months (2024-06-21)	28.61%

1 year (2023-12-22)	86.56%
2 years (2022-12-22)	322.94%
3 years (2021-12-22)	27.15%
5 years (2019-12-20)	458.41%

Is Protagonist Therapeutics stock undervalued or overvalued?

Valuing Protagonist Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Protagonist Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Protagonist Therapeutics's P/E ratio

Protagonist Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Protagonist Therapeutics shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Protagonist Therapeutics's EBITDA

Protagonist Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $150.1 million.

The EBITDA is a measure of a Protagonist Therapeutics's overall financial performance and is widely used to measure a its profitability.

Protagonist Therapeutics financials

Revenue TTM	$323.8 million
Gross profit TTM	$26.6 million
Return on assets TTM	19.96%
Return on equity TTM	40.97%
Profit margin	52.77%
Book value	$8.94
Market Capitalization more info button	$2.3 billion

TTM: trailing 12 months

Protagonist Therapeutics share dividends

We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.

Protagonist Therapeutics share price volatility

Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $21.43 up to $48.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 2.163. This would suggest that Protagonist Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Protagonist Therapeutics overview

Protagonist Therapeutics, Inc. , a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. .

Frequently asked questions

What percentage of Protagonist Therapeutics is owned by insiders or institutions?
Currently 1.133% of Protagonist Therapeutics shares are held by insiders and 107.297% by institutions. How many people work for Protagonist Therapeutics?
Latest data suggests 126 work at Protagonist Therapeutics. When does the fiscal year end for Protagonist Therapeutics?
Protagonist Therapeutics's fiscal year ends in December. Where is Protagonist Therapeutics based?
Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 What is Protagonist Therapeutics's ISIN number?
Protagonist Therapeutics's international securities identification number is: US74366E1029 What is Protagonist Therapeutics's CUSIP number?
Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102